Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organogenesis Holdings reports Q4 revenue decline but exceeds guidance

Organogenesis Holdings faced revenue decline in Q4 2022 but exceeded guidance expectations.
Operational progress in clinical trials and a healthy cash position are notable strengths.
Challenges include declining product sales and increased operating expenses.
Strategic investments and growth opportunities in clinical initiatives are key focus areas for 2023.

Organogenesis Holdings reports robust Q1 revenue growth and strategic focus

Organogenesis Holdings delivered strong revenue growth driven by Advanced Wound Care products, while facing challenges with increased expenses and a net loss.
The company's focus on innovation, market expansion, and cost management presents opportunities for sustained growth and competitive positioning.
Navigating regulatory requirements and market dynamics will be crucial for Organogenesis to capitalize on opportunities and mitigate challenges in the upcoming quarters.

Organogenesis Holdings faces revenue challenges amidst strong business trends

Organogenesis Holdings faced revenue challenges due to LCDs impacting products, leading to withdrawn guidance. Despite this, the company maintained a strong gross profit margin and focused on strategic sales shifts. Opportunities for growth exist in product focus and ongoing trials.

Organogenesis reports Q3 revenue decline, eyes growth amid regulatory shifts

Organogenesis Holdings navigated challenges in Q3 2023 with a focus on operational efficiency, financial strength, and strategic growth initiatives for the future.
While facing revenue declines and market uncertainties, the company capitalized on positive regulatory developments and operational advancements to drive performance.
Looking ahead, Organogenesis aims to address challenges, seize growth opportunities, and maintain its competitive edge in the evolving healthcare market landscape.

Organogenesis Holdings reports Q4 revenue decline but anticipates 2024 growth

Organogenesis Holdings faced challenges in Q4 but showed positive momentum and progress in clinical trials. The company expects revenue growth in 2024 and is focusing on customer engagement and new product launches for further expansion.

Organogenesis Holdings beats revenue expectations, eyes FDA approval for ReNu

Organogenesis Holdings demonstrated solid financial performance in Q1, with revenue exceeding expectations and improved operating metrics.
While facing challenges in certain revenue segments, the company's focus on innovation and regulatory progress presents growth opportunities.
Maintaining a strong cash position and reaffirming revenue guidance underscore Organogenesis' resilience and strategic outlook for the future.

Organogenesis Holdings exceeds Q3 revenue guidance, focuses on innovation

Organogenesis Holdings delivered a strong performance in Q3 2024, surpassing revenue guidance and demonstrating solid financial results.
While facing challenges such as potential market disruption and regulatory issues, the company remains focused on strategic initiatives and innovation to drive growth.
With opportunities in Medicare reimbursement, product development, and regulatory milestones, Organogenesis is well-positioned for future success and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2022.

Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results

NEW YORK , May 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Organogenesis Holdings Inc. (NASDAQ: ORGO). If you are a shareholder of Organogenesis Holdings Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/organogenesis-holdings-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Organogenesis Holdings Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2022 financial results will be reported after the market closes on Tuesday, May 10th.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

Don't be blinded by its attractive valuation.

Is This Healthcare Stock a Value Trap?

CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, has been named one of the Boston Business Journal's (BBJ) Middle Market Leaders, a ranking of the 50 highest growth companies in Massachusetts.

Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal

CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in Oppenheimer's 32nd Annual Healthcare Conference, which is being held virtually from March 15th-16th. Management will present on Tuesday, March 15th at 10:40 a.m. Eastern Time.

Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference

The company delivered quite an upside surprise with its fourth-quarter earnings release.

Why Organogenesis Holdings Stock Blasted 21% Higher Today

Organogenesis Holdings Inc's (NASDAQ: ORGO) Q4 FY21 sales increased 20% Y/Y to $128.6 million, beating the consensus of $124.70 million. The increase in net revenue was driven by a 30% increase in Advanced Wound Care product sales to $121.4 million, partially offset by a 45% decline.

Organogenesis' Q4 Profit Jumps More than 150% To $54M, Issues Solid FY22 Guidance

Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q4 2021 Results - Earnings Call Transcript

CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2021 and introduced financial guidance for the fiscal year ending December 31, 2022.

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February

Los Angeles, California--(Newsfile Corp. - February 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organogenesis Holdings Inc. ("Organogenesis" or "the Company") (NASDAQ: ORGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Deadline Today Alert: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Organogenesis Holdings Inc. (NASDAQ: ORGO) between March 17, 2021 and October 11, 2021, inclusive (the "Class Period"), of the important February 8, 2022 lead plaintiff deadline.SO WHAT: If you purchased Organogenesis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ORGO Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages Organogenesis Holdings Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - ORGO

New York, New York--(Newsfile Corp. - February 8, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Organogenesis securities between March 17, 2021 and October 11, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:...

ORGO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Organogenesis Holdings Inc. Investors of Class Action

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Organogenesis Holdings Inc. (NASDAQ: ORGO) alleging that the Company violated federal securities laws. Class Period: March 17, 2021 to October 11, 2021 Lead Plaintiff Deadline: February 8, 2022 No obligation or cost to you.

ORGO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Organogenesis Holdings Inc. Shareholders

Los Angeles, California--(Newsfile Corp. - February 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organogenesis Holdings Inc. ("Organogenesis" or "the Company") (NASDAQ: ORGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Organogenesis Holdings Inc. (NASDAQ: ORGO) between March 17, 2021 and October 11, 2021, inclusive (the "Class Period"), of the important February 8, 2022 lead plaintiff deadline.SO WHAT: If you purchased Organogenesis securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ORGO Final Deadline Tomorrow: Rosen, Globally Respected Investor Counsel, Encourages Organogenesis Holdings Inc. Investors with Losses to Secure Counsel Before Important February 8 Deadline in Securities Class Action - ORGO

CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2021 financial results will be reported after the market closes on Tuesday, March 1st.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Attention Organogenesis Holdings Inc. ("Organogenesis") (NASDAQ: ORGO) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 17, 2021 and October 11, 2021. If you suffered a loss on your investment in Organogenesis, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Organogenesis Investors of a Lead Plaintiff Deadline of February 8, 2022

SAN DIEGO--(BUSINESS WIRE)-- #ORGOstock--The suit alleges defendants issued false statements re: Organogenesis business and prospects, resulting in its stock trading at inflated prices.

TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ORGO

RADNOR, Pa.--(BUSINESS WIRE)---- $ORGO--Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis Holdings Inc. (ORGO) Investors of Filing Deadline in Class Action Lawsuit

Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis Holdings Inc. (ORGO) Investors of Filing Deadline in Class Action Lawsuit

RADNOR, Pa., Feb. 4, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Organogenesis Holdings Inc. ("Organogenesis") (NASDAQ: ORGO).

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Organogenesis Holdings Inc.

News for Organogenesis Holdings Stock (ORGO)